Figure 1
Figure 2
Figure 3
Immune-related adverse events
| IrAE of any grade | 20 (32%) |
| IrAE ≥ Grade 3/4 | 7 (11%) |
| Systemic corticosteroid use | 5 (8%) |
| Atezolizumab discontinuation due to IrAE | 7 (11%) |
Univariant and multivariant analysis of prognostic factors (correlation with overall survival)
| Subgroup | Univariant HR | p | Multivariant HR | p | Reference category |
|---|---|---|---|---|---|
| Age | 0.861 (0.428-1.731) | 0.675 | ≥ 75 years | ||
| ECOG PS | 2.883 (1.495-5.559) | 0.002 | 3.449 (1.358-8.761) | 0.009 | 2 or 3 |
| Visceral metastases* | 0.965 (0.502-1.853) | 0.914 | Yes | ||
| Clinical benefit to previous chemotherapy | 0.319 (0.133-0.765) | 0.010 | 0.355 (0.131-0.961) | 0.042 | Yes |
| TFI | 0.140 (0.032-0.604) | 0.008 | 0.113 (0.014-0.877) | 0.037 | > 6 months |
| IrAE | 0.566 (0.266-1.202) | 0.139 | Yes |
Patients’ characteristics
| Platinum-treated N=44 (%) | Platinum-naïve N=18 (%) | |
|---|---|---|
| Median age, years (range) | 65 (48-80) | 75 (62-85) |
| Age ≥ 75 years | 7 (16) | 12 (67) |
| Sex | ||
| Male/Female | 27 (61)/17 (39) | 11 (61)/7 (39) |
| ECOG PS | ||
| 0,1/2,3 | 26 (59)/18 (41) | 10 (56)/8 (44) |
| Primary metastatic disease | 23 (52) | 14 (78) |
| Metastatic nonvisceral/site visceral/hepatic | 14 (32)/30 (68)/18 (41) | 13 (72)/5 (28)/0 |
| Pure urothelial histology | 35 (80) | 15 (83) |
| PD-L1 status | ||
| 0-4% | 9 (20) | 1 (5) |
| ≥5 % | 10 (23) | 12 (67) |
| Unknown | 25 (57) | 5 (28) |
| Treatment modalities before atezolizumab | ||
| Perioperative chemotherapy | 14 (32) | |
| Surgery | 25 (57) | 10 (56) |
| Chemotherapy disease for metastatic Number of chemotherapy lines for metastatic disease before atezolizumab | 30 (68) | |
| 1/2 | 28 (93)/2 (7) |
Responses to treatment with atezolizumab
| Type of response | All patients N=57 (%) | Patients with liver metastases N=16 (28%) | Platinum-naive N=17 (30%) | Platinum-treated N=40 (70%) | ECOG PS 0+1 N=33 (58%) | ECOG PS 2+3 N=24 (42%) |
|---|---|---|---|---|---|---|
| CR | 5 (9) | 0 (0) | 3 (17.5) | 2 (5) | 4 (12) | 1 (4.2) |
| PR | 7 (12) | 1 (6) | 3 (17.5) | 4 (10) | 5 (15) | 2 (8.3) |
| SD | 7 (12) | 4 (25) | 1 (6) | 6 (15) | 6 (18) | 1 (4.2) |
| PD | 38 (67) | 11 (69) | 10 (59) | 28 (70) | 18 (55) | 20 (83.3) |